Approval of deflazacort oral suspension is for patients 5 years of age and older
FRIDAY, June 14, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved the first generic version of Emflaza (deflazacort) oral suspension for Duchenne muscular dystrophy (DMD).
Deflazacort oral suspension is a corticosteroid indicated to treat DMD in patients 5 years of age and older but is contraindicated in patients with known hypersensitivity to deflazacort. The most common adverse reactions reported in patients were Cushingoid appearance, weight increase, increase in appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis.
“Duchenne muscular dystrophy is a devastating rare disease, and with limited treatment options available there is a critical need for the greater accessibility that a generic therapy can bring,” Ketan Mehta, the founder and CEO of Tris Pharma, said in a statement. “This FDA approval is a significant milestone for the patients, caregivers, and physicians who may depend on this medication to treat DMD.”
Approval of the generic version of Emflaza oral suspension was granted to Cranbury Pharmaceuticals, a subsidiary of Tris Pharma.
Deramiocel Can Safely Slow Progression in Advanced Duchenne Muscular Dystrophy 
BIND Screener Can ID Brain-Related Comorbidities in Duchenne Muscular Dystrophy 
Most Speakers at FDA Advisory Committee Meetings Support Drug Approval 
Countries Involved in U.S. Clinical Trials Do Not Gain Timely Access to Approved Medicines .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV 
Racial, Ethnic Differences Seen in Inhaler Use for Asthma in U.S. Adults 
Nutritional Guidance Lacking for Adults Receiving Semaglutide, Tirzepatide 
Zoliflodacin Noninferior for Uncomplicated Urogenital Gonorrhea 
